K
46.72
-0.31 (-0.66%)
| Previous Close | 47.03 |
| Open | 46.69 |
| Volume | 335,203 |
| Avg. Volume (3M) | 643,705 |
| Market Cap | 3,575,732,736 |
| Price / Earnings (TTM) | 62.29 |
| Price / Earnings (Forward) | 59.52 |
| Price / Sales | 5.47 |
| Price / Book | 6.31 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2026 |
| Profit Margin | -3.52% |
| Operating Margin (TTM) | 9.63% |
| Diluted EPS (TTM) | -0.240 |
| Quarterly Revenue Growth (YOY) | 72.50% |
| Total Debt/Equity (MRQ) | 2.17% |
| Current Ratio (MRQ) | 3.66 |
| Operating Cash Flow (TTM) | 44.03 M |
| Levered Free Cash Flow (TTM) | 25.15 M |
| Return on Assets (TTM) | -1.77% |
| Return on Equity (TTM) | -3.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Kiniksa Pharmaceuticals Interna | Bullish | Bullish |
AIStockmoo Score
-0.4
| Analyst Consensus | 4.0 |
| Insider Activity | -3.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.40 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 3.80% |
| % Held by Institutions | 97.31% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 62.00 (Canaccord Genuity, 32.71%) | Buy |
| Median | 53.00 (13.44%) | |
| Low | 53.00 (Wedbush, 13.44%) | Buy |
| 53.00 (Wells Fargo, 13.44%) | Buy | |
| Average | 56.00 (19.86%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 44.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 25 Feb 2026 | 53.00 (13.44%) | Buy | 42.76 |
| Wells Fargo | 25 Feb 2026 | 53.00 (13.44%) | Buy | 42.76 |
| Canaccord Genuity | 19 Feb 2026 | 62.00 (32.71%) | Buy | 47.17 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MEGNA MICHAEL R | - | 48.14 | -8,291 | -395,095 |
| MOAT ROSS | - | 48.61 | -4,844 | -235,767 |
| PAOLINI JOHN F. | - | 48.94 | -1,208 | -59,120 |
| PATEL SANJ K | - | 49.25 | -12,109 | -597,054 |
| QUART BARRY D | - | 49.55 | -6,901 | -341,945 |
| RAGOSA MARK | - | 48.94 | -1,303 | -63,769 |
| TESSARI EBEN | - | 48.94 | -846 | -41,403 |
| Aggregate Net Quantity | -35,502 | |||
| Aggregate Net Value ($) | -1,734,153 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 48.81 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOAT ROSS | Officer | 09 Apr 2026 | Automatic sell (-) | 1,703 | 47.33 | 80,603 |
| MEGNA MICHAEL R | Officer | 09 Apr 2026 | Automatic sell (-) | 6,625 | 47.33 | 313,561 |
| MEGNA MICHAEL R | Officer | 07 Apr 2026 | Disposed (-) | 1,666 | 48.94 | 81,534 |
| MEGNA MICHAEL R | Officer | 07 Apr 2026 | Option execute | 3,932 | - | - |
| MOAT ROSS | Officer | 07 Apr 2026 | Disposed (-) | 774 | 48.94 | 37,880 |
| MOAT ROSS | Officer | 07 Apr 2026 | Option execute | 2,477 | - | - |
| PAOLINI JOHN F. | Officer | 07 Apr 2026 | Disposed (-) | 1,208 | 48.94 | 59,120 |
| PAOLINI JOHN F. | Officer | 07 Apr 2026 | Option execute | 2,497 | - | - |
| PATEL SANJ K | Officer | 07 Apr 2026 | Disposed (-) | 4,831 | 48.94 | 236,429 |
| PATEL SANJ K | Officer | 07 Apr 2026 | Option execute | 9,991 | - | - |
| RAGOSA MARK | Officer | 07 Apr 2026 | Disposed (-) | 1,303 | 48.94 | 63,769 |
| RAGOSA MARK | Officer | 07 Apr 2026 | Option execute | 2,694 | - | - |
| TESSARI EBEN | Officer | 07 Apr 2026 | Disposed (-) | 846 | 48.94 | 41,403 |
| TESSARI EBEN | Officer | 07 Apr 2026 | Option execute | 2,726 | - | - |
| QUART BARRY D | Director | 06 Apr 2026 | Automatic sell (-) | 6,901 | 49.55 | 341,945 |
| QUART BARRY D | Director | 06 Apr 2026 | Option execute | 6,901 | - | - |
| MOAT ROSS | Officer | 06 Apr 2026 | Automatic sell (-) | 2,367 | 49.55 | 117,285 |
| PATEL SANJ K | Officer | 06 Apr 2026 | Automatic sell (-) | 7,278 | 49.55 | 360,625 |
| PATEL SANJ K | Officer | 06 Apr 2026 | Option execute | 7,278 | - | - |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |